Search Results

search

Search Filters

Organization
Purdue Research Foundation
Eradivir Phase 2 challenge study of EV25
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
March 10, 2025 08:01 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., March 10, 2025 (GLOBE NEWSWIRE) -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral...
Crystallization Systems Technology Inc. (CrySyst) co-founder Zoltán Nagy
High-tech startup CrySyst provides quality-by-control solutions for pharmaceutical, fine chemical industries
March 03, 2025 08:15 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- International process systems and operation experts have launched high-tech startup Crystallization Systems Technology Inc. (CrySyst) to...
Amplified Sciences leadership
Amplified Sciences earns CLIA certification for its first test to assess pancreatic cancer risk
February 19, 2025 09:01 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging...
Ángel Enríquez, CEO, Emboa Medical
Emboa Medical creates, validates novel catheter to improve stroke patients’ outcomes
February 18, 2025 09:01 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emboa Medical Inc., a medical device startup, has mimicked a snake’s evolutionary advantage to improve the retrieval of blood clots that cause...
Eradivir employee // PNAS peer-reviewed research publication
Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
November 21, 2024 09:24 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that licenses innovations from Purdue Research Foundation, has developed a patent-pending antiviral...
Lead exposure level assessment method, Aaron Specht, Purdue University
Purdue innovations detect lead exposure faster, easier and with greater precision at the point of care
October 31, 2024 09:57 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Exposure to lead can adversely impact people’s health in several ways. A Purdue University researcher in the College of Health and Human...
Eradivir $10.25M Series A funding round
Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic
September 25, 2024 10:00 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The...
Eradivir logo
Biotech company Eradivir is developing lead drug EV25 to treat influenza
July 09, 2024 14:24 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to...
Tillmann Kubis Headshot
From eureka moments to industry impact: Tillmann Kubis’ quantum code library
July 08, 2024 10:59 ET | Purdue Research Foundation
WEST LAFAYETTE, IND., July 08, 2024 (GLOBE NEWSWIRE) -- You could talk to Tillmann Kubis for hours. His laid-back demeanor and desire for everyone to understand what he’s working on is so...
Herman Sintim, Purdue University
‘Like a hand fitting into a glove’: Purdue-engineered compound designed to treat drug-resistant acute myeloid leukemia
June 20, 2024 10:55 ET | Purdue Research Foundation
WEST LAFAYETTE, Ind., June 20, 2024 (GLOBE NEWSWIRE) -- Researchers at Purdue University’s College of Science have developed a patent-pending compound called HSN748 to treat drug-resistant acute...